Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.36 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HPN | P05981 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130760 | 0.71 | CA2 (0.36) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6308900 | 0.71 | CA2 (0.40) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL10388767 | 0.70 | ALDH1A1 (0.50) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL27358164 | 0.70 | KDM4E (0.31) | SMN1; SMN2ALDH1A1CYP1A2ALOX15MAPT | |
| SCHEMBL7522243 | 0.70 | CA2 (0.35) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL15173818 | 0.69 | CA2 (0.59) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL7524824 | 0.68 | CA2 (0.33) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL7732349 | 0.68 | CA2 (0.33) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL7522979 | 0.68 | CA2 (0.33) | CA2CA1SMN1; SMN2ALDH1A1POLB | |
| Dimethylamine SCHEMBL6307740 | 0.68 | CA2 (0.37) | CA2CA1SMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159476-A1 | Pharmaceutical composition for preventing or treating respiratory disease | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-07-21 | — | — | US | disclosed |
| US-6440999-B1 | Intimal thickening inhibitory agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-27 | — | — | US | disclosed |
| EP-0791589-B1 | 4,6-DI-t-BUTYL-2,3-DIHYDROBENZOTHIOPHENES WHICH INHIBIT LDL OXIDATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-03-06 | — | — | EP | disclosed |
| CN-1073563-C | 4, 6-di-tert-butyl-2, 3-dihydrobenzothiophene derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-10-24 | — | — | CN | disclosed |
| US-6133279-A | A 2,6-DI-T-BUTYLPHENOL DERIVATIVE FOR RENAL DISEASES, E.G., CHRONIC RENAL FAILURE, DIABETIC NEPHROPATHY GLOMERULAR NEPHRITIS, IMMUNOCOMPLEX NEPHRITIS AND ACUTE RENAL FAILURE; CYTOPROTECTIVE AGENT THAT INHIBITS THE LIPID PEROXIDATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6103753-A | ADMINISTERING TO A PATIENT FOR INHIBITING THICKENING OF VASCULAR STENOSIS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, A 2,6-DI-T-BUTYLPHENOL DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0950405-A1 | REMEDIES FOR RENAL DISEASES AND ORGAN-PRESERVING AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-10-20 | — | — | EP | disclosed |
| CN-1204259-A | Intimal thickening inhibitor | SHONAN KIKO K K (JP) | 1999-01-06 | — | — | CN | disclosed |
| EP-0868913-A1 | INTIMAL THICKENING INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5789436-A | ARTERIOSCLEROSIS; INHIBITORS OF OXIDATION OF LOW DENSITY LIPOPROTEINS; | CHUGAI SEIYAK KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0791589-A1 | 4,6-DI-t-BUTYL-2,3-DIHYDROBENZOTHIOPHENES WHICH INHIBIT LDL OXIDATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-27 | — | — | EP | disclosed |
| CN-1148386-A | 4,6-di-5-butyl-2,3-dihydrobenzothiophene derivative | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1997-04-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159476-A1 | Pharmaceutical composition for preventing or treating respiratory disease | CFTR, CMA1, SLC5A1 | CA2 329/4885CA1 1755/4885SMN1; SMN2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.